Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.
- NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_assertion description "[Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.
- NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_assertion evidence source_evidence_literature NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.
- NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_assertion SIO_000772 19204207 NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.
- NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_assertion wasDerivedFrom gad-20150221 NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.
- NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_assertion wasGeneratedBy ECO_0000203 NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.
- gad-20150221 importedOn "2015-02-21" NP109691.RAA55I6dNqppP2mqMkq9wW4a4sjcQoFRwDaKXrA2JcAfM130_provenance.